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Abstract
Background—HIV infection has been associated with development of prediabetes and diabetes.
Optimum screening practices for these disorders in HIV-infected populations remain unclear.
Methods—We screened 377 adults, with- or at-risk for HIV infection, for incident
hyperglycaemia (prediabetes or diabetes) using two oral glucose tolerance tests (OGTTs) a median
of 18.6 months apart. We determined proportion of incident cases detected by fasting and 120-min
plasma glucose levels. Independent predictors of incident hyperglycaemia were identified using
logistic regression.
Results—The baseline OGTT was consistent with diabetes in 7% of participants and with
prediabetes in 31%. Among 352 normoglycaemic and prediabetic participants at baseline, 19 (5%)
developed diabetes on follow-up. Among participants normoglycaemic at baseline, an additional
38 (16%) developed prediabetes. Overall 52% of incident hyperglycaemia cases were detected by
fasting plasma glucose alone, 33% by a 120-min glucose level alone and 15% by both. Factors
independently associated with incident hyperglycaemia included age ≥50 years and body mass
index ≥30 kg/m2. Neither HIV infection nor highly active antiretroviral therapy (HAART) use
were associated with increased risk of diabetes.
Conclusions—Incident hyperglycaemia is common among older adults with or at-risk for HIV
infection. HIV-infected individuals with classic diabetes risk factors should be screened for
hyperglycaemia regardless of HAART use. OGTTs may be the preferred screening strategy in
HIV-infected individuals at high risk for developing hyperglycaemia.
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Highly active antiretroviral therapy (HAART) has prolonged the lifespan of individuals
infected with HIV [1]. This increased longevity makes HIV-infected individuals more likely
to experience diseases of mid- and later life, such as diabetes mellitus [2, 3] and
cardiovascular disease [1, 4]. The increased risk of diabetes among HIV-infected individuals
has largely been attributed to HAART use [5, 6], although coinfection with HCV [7–10] and
classic diabetes risk factors [11–14] may also play a role.
As early treatment may prevent end-organ damage [15], screening for diabetes is warranted
in individuals at increased risk for this disease. Identification of individuals with prediabetes
is also desirable, as interventions can prevent or delay the development of diabetes [16], as
well as improve cardiovascular risk profiles [17]. Guidelines based on expert opinion
recommend obtaining fasting plasma glucose levels before initiating therapy, 3–6 months
after starting therapy, then annually thereafter [18]. An oral glucose tolerance test (OGTT) is
recommended in patients with classic diabetes risk factors [18], such as older age, obesity
and having a first-degree relative with diabetes [19]. There are data to suggest that OGTTs
are more sensitive than fasting plasma glucose levels [20]; however, in clinical practice,
fasting plasma glucose levels are more commonly obtained. In addition, recommendations
regarding the frequency of screening these individuals at high risk for diabetes have not
been rigorously tested [18].
We performed serial screening for prediabetes and diabetes mellitus among participants in
two cohorts of middle-aged and older adults with or at-risk for HIV infection, analysed
factors associated with incident cases, and investigated how case detection differed by
measurements of fasting and 120-min glucose levels during an OGTT.
Methods
Study participants
Details about participant recruitment and study design have been published [10, 12]. Briefly,
between July 2002 and January 2005, participants were recruited from two cohorts of adults
with or at-risk for HIV infection, the Menopause Study (Ms) and the Cohort of HIV at-risk
Aging Men’s Prospective Study (CHAMPS) in the Bronx, NY, USA. Ms and CHAMPS
enrolled adults who either had documented HIV infection, or were at risk of acquiring HIV
through self-reported illicit drug use or high-risk sexual behaviours [21, 22]. Ms and
CHAMPS participants were followed with semi-annual research visits, during which a
structured interview was administered, blood was drawn for HIV serology and T-
lymphocyte studies, and weight and height were measured according to a standardized
protocol. To be enrolled in the present study, participants were required to meet criteria for
inclusion in one of the following groups: HIV-uninfected; HIV-infected and antiretroviral-
naive (‘no HAART’); HIV-infected, currently taking HAART and protease inhibitor (PI)-
naive (‘non-PI-HAART’); or HIV-infected and currently taking HAART including a PI (‘PI-
HAART’). Exclusion criteria included a history of diabetes, self-reported antidiabetic
medication use, pregnancy or poor venous access. The study was approved by the
Institutional Review Boards for the protection of human subjects of both Montefiore
Medical Center (Bronx, NY, USA) and Albert Einstein College of Medicine (Bronx, NY,
USA), and all participants provided written informed consent. All procedures were in
accordance with the revised Declaration of Helsinki.
Interview data
Trained research staff conducted a standardized face-to-face interview to elicit information
on sociodemographic characteristics, family and medical history, and antiretroviral use with
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the aid of pill chart prompts. Information on physical activity and drug use behaviors was
assessed using the audio computer-assisted self-interviewing technique. At each visit,
participants were asked whether they had received a diagnosis of diabetes (or ‘high blood
sugar’), their age at the time of diagnosis and whether they were taking diabetes
medications.
Oral glucose tolerance test
Participants underwent two OGTTs a median of 18.6 months apart (interquartile range 18.1–
19.9 months) according to World Health Organization procedures [23]. For each OGTT,
participants were instructed to report to the Albert Einstein General Clinical Research
Center (Bronx, NY, USA) after a 10–16 h overnight fast, and to take their morning dose of
medications with water. A 75 g bolus of dextrose in water was administered orally over <5
min. Blood samples were drawn immediately before and 120 min after the dextrose
ingestion. Waist circumference was measured at each OGTT visit according to a
standardized protocol.
Biochemical and immunologic assays
Specimens for glucose determination were collected at 0 and 120 min during the OGTT in
tubes with glycolytic inhibitors. Plasma glucose was measured using the hexokinase method.
HCV antibody testing was performed by enzyme immunoassay (ELISA 3.0; Ortho-Clinical
Diagnostics, Raritan, NJ, USA) using blood samples obtained at the first OGTT. For HCV-
seropositive participants, HCV RNA quantification was performed on blood samples
obtained at both OGTTs using the Versant HCV RNA assay (Bayer Corporation, Tarrytown,
NY, USA), which has a lower limit of detection of 615 IU/ml.
Outcome variables
The primary outcome variable was hyperglycaemia, which included both prediabetes and
diabetes. Prediabetes was defined as a fasting plasma glucose level ≥100 mg/dl and <126
mg/dl (impaired fasting glucose [IFG]) or a 120-min glucose level ≥140 mg/dl and <200
mg/dl (impaired glucose tolerance [IGT]) during an OGTT, according to American Diabetes
Association criteria (ADA) criteria [24]. Diabetes was defined as a fasting plasma glucose
level ≥126 mg/dl or a 120-min glucose level ≥200 mg/dl during an OGTT [24] or self-
reported use of anti-diabetic medication.
Exposure variables
Exposure variables were based on data collected at the research visit most proximate to the
second OGTT. The primary exposure variable was HIV-HAART status, classified as HIV-
uninfected; HIV-infected, no HAART; HIV-infected, non-PI-HAART; and HIV-infected,
PI-HAART. Abdominal obesity was defined as a waist circumference of >88 cm (35 inches)
in women or >102 cm (40 inches) in men, according to American Heart Association criteria
for the metabolic syndrome [25]. Physical activity was defined as moderate or strenuous
exercise for ≥20 min on >1 day/week. HCV infection was defined as seropositivity and at
least one detectable HCV RNA level.
Data analysis
Univariate associations of participant characteristics with incident hyperglycaemia were
determined using the χ2 or Fisher’s exact test for categorical variables, and the Mann-
Whitney U test for continuous variables. Variables considered included HIV-HAART status
(HIV-uninfected; HIV-infected, no HAART; HIV-infected, non-PI-HAART; and HIV-
infected, PI-HAART), age ≥50 years, race/ethnicity (Black, Hispanic or White/other),
family history of diabetes, body mass index (BMI; <25, 25–29.9 or ≥30 kg/m2), abdominal
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obesity, physical activity, HCV status, methadone maintenance, heroin use and crack or
cocaine use. Multivariate logistic regression analysis was performed to assess independent
predictors of incident hyperglycaemia. In constructing multivariate models, we included
HIV-HAART status in addition to factors with P ≤0.2 on univariate analysis. SPSS software
version 18 (SPSS Inc., Chicago, IL, USA) was used for all analyses. Statistical significance
was determined using two-tailed tests with α=0.05.
Results
Participant characteristics
Of the 447 Ms and CHAMPS participants who had a baseline OGTT, 377 (84%) returned
for a second OGTT and are included in this analysis. Participants who returned for a second
OGTT had similar sociodemographic characteristics and HIV and HCV prevalence rates
compared to those who did not return, but were less likely to report crack, cocaine or heroin
use in the last 6 months at enrollment (27% versus 46%; P=0.002).
Baseline participant characteristics are presented in Table 1. Of the 377 participants, 222
(59%) were HIV-infected. The majority (79%) of HIV-infected participants were
antiretroviral-experienced at baseline. Compared with HIV-uninfected participants, HIV-
infected participants were more often Black or Hispanic, less often employed and obese, and
less likely to have used drugs in the last 5 years. There were no HIV seroconversions during
follow-up.
A total of 217 (58%) participants were HCV-seropositive, and of these 159 (73%) had active
HCV infection determined by at least one detectable HCV RNA level during follow-up,
with no difference by HIV serostatus. Among the 125 HCV seropositive participants with
both a detectable HCV RNA at baseline and an injection drug use history, we estimated their
median duration of HCV infection as 34 years (interquartile range 25–37) using age at first
injection as a surrogate for age at HCV acquisition. A total of 14 participants reported prior
treatment with interferon; of these, 1 had evidence of HCV viral clearance.
Diabetes risk factors were prevalent: 155 (41%) participants had a first-degree relative with
diabetes, 242 (64%) had a BMI ≥25 kg/m2, and 147 (40%) had abdominal obesity. At
baseline, 25 of 377 (7%) participants had an OGTT consistent with diabetes and 115 of 377
(31%) with prediabetes, with no difference by HIV status. Among the 115 participants with
prediabetes, 58 (50%) had IFG only, 33 (29%) had IGT only and 24 (21%) had both IFG
and IGT, with no difference by HIV status.
Incident hyperglycaemia
Hyperglycaemia case ascertainment is depicted in Figure 1. Among 352 participants without
diabetes at baseline, 19 (5%) developed diabetes on follow-up, of whom 16 were diagnosed
by OGTT and 3 self-reported new use of anti-diabetic medication. Incident cases of diabetes
were more common among those with prediabetes at baseline (11/115, 10%) than among
those with normoglycaemia (8/237, 3%; P=0.016). Of the 237 participants who were
normoglycaemic at baseline, 46 (19%) had incident hyperglycaemia, among whom 38
(16%) developed prediabetes and 8 (3%) developed diabetes. HIV-infected participants were
less likely to develop hyperglycaemia than HIV-uninfected participants (15% for HIV-
infected versus 26% for HIV-uninfected; P=0.038).
The proportions of incident prediabetes and diabetes cases detected by different screening
tests are shown in Figure 2. Of the 16 participants with a screening test consistent with
incident diabetes, 7 (44%) cases were detected only by a fasting plasma glucose level, 5
(31%) were detected only by the 120-min plasma glucose level on OGTT and 4 (25%) were
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detected by both tests, with no difference by HIV status. Among the 38 participants who
developed prediabetes, 21 (55%) cases were detected only by a fasting plasma glucose level,
13 (34%) were detected only by the 120-min plasma glucose level on OGTT and 4 (11%)
were detected by both tests, with no difference by HIV status.
Of 145 HIV-infected participants who were normoglycaemic at baseline, 22 (15%) had
incident hyperglycaemia, among whom 19 (13%) developed prediabetes and 3 (2%)
diabetes. A total of 28 participants who were normoglycaemic at baseline were HAART-
naive, and 3 of these participants started HAART (PI-containing) during follow-up. Overall,
1 of 3 of those who started HAART developed prediabetes compared to 3 of 25 (12%) of
those who remained HAART-naive (P=0.38), and none developed diabetes. Among 65 HIV-
infected participants who had prediabetes at baseline, 6 developed incident diabetes; those
with IGT alone (3/21, 14%) or both IGT and IFG (3/17, 18%) tended to progress to diabetes
more often than those with IFG alone (0/27, 0%; P=0.056).
Factors associated with incident hyperglycaemia
Among 237 participants who were normoglycaemic at baseline, factors associated with
incident hyperglycaemia (prediabetes or diabetes) included age ≥50 years (odds ratio [OR]
2.2, 95% confidence interval [CI] 1.1–4.4), BMI ≥30 kg/m2 (reference <25.0; OR 3.0, 95%
CI 1.3–6.5), and abdominal obesity (OR 2.9, 95% CI 1.5–5.7).
As BMI and abdominal obesity were highly correlated, two multivariate models were
constructed that differed only by inclusion of one of these variables. In model 1, factors
independently associated with incident hyperglycaemia included abdominal obesity
(Adjusted OR [ORadj] 4.3, 95% CI 2.0–9.2) and age ≥50 years (ORadj 2.9, 95% CI 1.3–6.5).
In model 2, factors associated with incident hyperglycaemia included BMI (reference <25.0;
ORadj 2.0, 95% CI 0.8–4.8 for BMI 25.0–29.9 kg/m2; ORadj 4.9, 95% CI 2.0–11.9 for BMI
≥30 kg/m2), age ≥50 years (ORadj 2.7, 95% CI 1.2–5.9), and HIV-infected, no HAART
(reference HIV-uninfected; ORadj 0.3, 95% CI 0.1–0.9). Use of PI-HAART and non-PI
HAART were not associated with incident hyperglycaemia in either model. Adding family
history of diabetes to the final models did not significantly change the results.
In analyses restricted to HIV-infected participants, neither HCV nor HAART use predicted
hyperglycaemia (SP et al., data not shown).
Discussion
In this cohort of middle-aged and older adults with or at-risk for HIV infection, we found
that incident diabetes occurred in 5% of at-risk participants, and incident hyperglycaemia in
19% of participants, after a median follow-up time of 18.6 months. Among the 54 new cases
of hyperglycaemia diagnosed by OGTT, one-third had an isolated increased 120-min plasma
glucose level. Participants with prediabetes at baseline were more likely to develop diabetes
than those who were normoglycaemic. Traditional diabetes risk factors, including older age,
BMI ≥30 kg/m2 and abdominal obesity, were associated with incident hyperglycaemia,
whearas HAART use with or without a PI was not. Surprisingly, HIV infection in the
absence of HAART was inversely associated with risk of incident hyperglycaemia in some
models; a biological explanation for this finding is not obvious, and further study is
necessary to assess whether such an association can be confirmed.
Although HIV-infected individuals appear to be at high risk for developing hyperglycaemia
[5, 6, 12, 26], data on the optimal screening strategy in this population are lacking.
Guidelines based on expert opinion have focused on obtaining fasting plasma glucose levels
after initiating or switching HAART regimens, particularly in the presence of a PI [18, 27].
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We did not find an association between HAART use and incident hyperglycaemia when
compared to HIV-uninfected individuals, in contrast to another study which did not control
for several key factors associated with diabetes including family history of diabetes and
HCV status [5]. We also did not find an association between HCV infection and incident
hyperglycaemia, although previously we reported that HCV infection was strongly
associated with greater insulin resistance in this cohort [10]. Rather, we found that
traditional diabetes risk factors, including age ≥50 years, BMI ≥30 kg/m2 and abdominal
obesity were predictors of incident hyperglycaemia. The high prevalence of diabetes risk
factors in our cohort may have minimized the contribution of HAART and HCV infection to
incident diabetes. In the Veterans Aging Cohort Study, traditional diabetes risk factors,
including older age and BMI, had a greater impact on diabetes risk in HIV-infected
participants than in uninfected participants, and were associated with a greater risk for
diabetes than HAART use [28]. Our findings may also be partially attributable to changing
patterns of antiretroviral use, as newer PIs have less of an effect on insulin sensitivity than
indinavir [29–31], which was commonly used early in the HAART era. Among HIV-
infected individuals, cumulative exposure to NRTIs, particularly thymidine analogues, has
been associated with risk of diabetes in some studies [3, 32], which might be attributable to
NRTI-induced mitochondrial dysfunction [33].
According to guidelines from the ADA, older age and being overweight or obesity are the
main risk factors to consider when targeting individuals in the general population for
diabetes screening [19]. ADA recommends that all asymptomatic individuals aged 45 years
and older should be screened for hyperglycaemia, as should individuals younger than 45
years who have a BMI ≥25 kg/m2 and at least one additional diabetes risk factor [19]. In this
study of middle aged and older men and women, of the 24% of participants younger than 45
years without diabetes at baseline, 69% had a BMI ≥25 kg/m2 and at least one additional
diabetes risk factor. Also of note, we found that 31% of incident diabetes cases and 34% of
incident prediabetes cases had isolated increased 120-min plasma glucose levels, and thus
would not have been detected if only a fasting plasma glucose level was measured. Others
have also found that performing only a fasting glucose measurement in HIV-infected
populations might miss an appreciable number of individuals with diabetes [34]. Taken
together, these data suggest that similar to HIV-uninfected patients, all HIV-infected patients
should be assessed for diabetes risk factors regardless of HAART use, and those with risk
factors should undergo screening with an OGTT when possible.
Further studies are needed to determine the optimal interval between diabetes screening tests
in HIV-infected individuals. The ADA recommends that for those with normal glucose
levels on screening, the test should be repeated in 3 years, whereas for individuals with
prediabetes, testing should be repeated annually [19]. These time intervals were determined
by expert consensus or clinical experience. We detected an appreciable number of new
hyperglycaemic cases after a median follow-up time of just 18.6 months, suggesting that
perhaps an annual interval between screening tests is prudent for individuals with or at risk
for HIV infection.
Identification of prediabetes has important clinical implications. Prediabetes increases one’s
risk for diabetes [16], for other cardiovascular risk factors such as hypertension and
dyslipidemia [35, 36], and for cardiovascular death [37]. Increased risk of cardiovascular
events begins as early as 15 years prior to the diagnosis of diabetes [38]. There is a
mounting body of evidence that an elevated 120-min plasma glucose level, and not a fasting
plasma glucose level, is a more important predictor of cardiovascular morbidity and
mortality among patients with IGT and diabetes [36, 39]. HIV-infected populations are at
particularly high risk for cardiovascular disease as they have a high prevalence of other
cardiovascular risk factors, including smoking [40, 41], obesity [3, 42, 43] and dyslipidemia
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[44]. Thus screening for hyperglycaemia with an OGTT, which is inexpensive and easy to
perform, would allow for early interventions to prevent morbidity and mortality in this
vulnerable population.
Clinical interventions in prediabetic individuals have demonstrated improvement in
cardiovascular risk profiles. The Diabetes Prevention Program, a multicenter clinical trial
that enrolled overweight or obese prediabetic adults, found that individuals randomized to
intensive lifestyle modification or administration of metformin had significant reductions in
incident diabetes compared to placebo (58% and 31%, respectively) [16]. These
interventions also reduced levels of two non-traditional cardiovascular risk markers, C-
reactive protein and fibrinogen [17]. Equivalent intervention strategies have not been tested
in HIV-infected populations. However, diligence in screening for hyperglycaemia should
prompt counseling on weight loss and increased physical activity in patients with newly
diagnosed prediabetes and diabetes.
Our study had several strengths. Whereas most other studies in HIV-infected populations
have defined diabetes by self-report or fasting plasma glucose levels alone, we conducted
OGTTs, which increased the sensitivity of case ascertainment. We also collected specimens
for glucose determination in grey top tubes with glycolytic inhibitors to decrease the false
negative rate. In addition, we included a comparison group of HIV-uninfected participants
with demographic and behavioral characteristics similar to those of the HIV-infected
participants.
Our study also had some limitations. Similar to other epidemiologic studies, abnormal
diagnostic tests were not confirmed on a different day as is recommended by the ADA [24].
We also had a small number of incident cases, which may have limited our ability to detect
associations between certain risk factors and incident hyperglycaemia.
In summary, in this cohort of HIV-infected and at-risk individuals, we found that repeat
screening with an OGTT after a median of 18.6 months detected incident hyperglycaemia in
19% of participants. HIV-infected individuals most likely to benefit from screening are
those with classic diabetes risk factors such as age ≥50 years, BMI ≥30 kg/m2 and
abdominal obesity. Screening with a 2-hour OGTT may be preferable to screening with a
fasting plasma glucose level alone in high-risk patients. Early detection of hyperglycaemia
provides opportunities to intervene to prevent diabetes progression and modify
cardiovascular risk factors.
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Figure 1. Hyperglycaemia case ascertainment
Hyperglycaemia case ascertainment among 377 individuals with two oral glucose tolerance
tests (OGTTs) a median of 18.6 months apart. aOne case with normoglycaemia and two
cases with prediabetes at baseline self-reported use of anti-diabetic medications on follow-
up, for whom a second OGTT was not performed.
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Figure 2. Proportion of incident prediabetes and diabetes cases by screening test
A total of 55% of prediabetes cases and 44% of diabetes cases were detected by a fasting
plasma glucose level alone; 34% of prediabetes cases and 31% of diabetes cases were
detected by a 120-min plasma glucose level alone; and 11% of prediabetes cases and 25% of
diabetes cases were detected by both fasting and 120-min plasma glucose levels.
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Table 1
Baseline Participant Characteristics
Characteristic HIV-uninfected (n=155) HIV-infected (n=222)
Median age, years (range) 50 (37–73) 50 (35–68)
Male, n (%) 76 (49) 104 (47)
Race/ethnicitya
 Black, n (%) 71 (46) 135 (61)
 Hispanic, n (%) 52 (34) 59 (27)
 White/Other, n (%) 32 (21) 28 (13)
Employed, n (%)a 35 (23) 28 (13)
Family history of diabetes, n (%) 69 (45) 86 (39)
Body mass indexa
 <25.0 kg/m2 (lean/normal), n (%) 48 (31) 87 (39)
 25–29.9 kg/m2 (overweight), n (%) 50 (32) 82 (37)
 ≥30 kg/m2 (obese), n (%) 57 (37) 53 (24)
Abdominal obesity, n (%)b 68 (45) 79 (36)
Physical activity, n (%)c 55 (36) 59 (27)
Drug use in the prior 5 years
 Heroin, n (%)a 57 (37) 47 (21)
 Crack or cocaine, n (%) 87 (56) 110 (50)
Drug use in the prior 6 months
 Heroin, n (%)a 23 (15) 15 (7)
 Crack or cocaine, n (%) 35 (23) 51 (23)
Current methadone maintenance, n (%) 22 (14) 18 (8)
HCV status
 HCV-seronegative, n (%) 66 (43) 94 (42)
 HCV-seropositive, undetectable RNA, n (%) 27 (17) 31 (14)
 HCV-seropositive, detectable RNA, n (%) 62 (40) 97 (44)
Antiretroviral use
 No HAART, n (%) 47 (21)
 Non-PI-HAART, n (%) 55 (25)
 PI-HAART, n (%) 120 (54)
CD4+ T-cell count
aP < 0.05. for χ2 test.
aP < 0.05. for χ2 test.
aP < 0.05. for χ2 test.
bAbdominal obesity is defined as a waist circumference of >88 cm (35 inches) in women or >102 cm (40 inches) in men[25].
cPhysical activity is defined as moderate or strenuous exercise for ≥20 min on >1 day/week.
aP < 0.05. for χ2 test.
aP < 0.05. for χ2 test.
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Characteristic HIV-uninfected (n=155) HIV-infected (n=222)
 ≤200 cells/μl, n (%) 32 (15)
 201–500 cells/μl, n (%) 99 (45)
 >500 cells/μl, n (%) 90 (41)
Zidovudine use, n (%) 13 (6)
Stavudine use, n (%) 67 (30)
Median fasting glucose, mg/dl (range) 93 (55–351) 92 (53–217)
Median 120-min glucose, mg/dl (range) 105 (42–477) 109 (54–299)
OGTT results
 Normal, n (%) 92 (59) 145 (65)
 Prediabetes, n (%) 50 (32) 65 (29)
  IFG, n (%) 31 (62) 27 (42)
  IGT, n (%) 12 (24) 21 (32)
  IFG and IGT, n (%) 7 (14) 17 (26)
  Diabetes mellitus, n (%) 13 (8) 12 (5)
Because of rounding, percentages may not total 100. Missing data is as follows: employed (n=4),abdominal obesity (n=6),used heroin in prior 5
years (n=1),used heroin or crack/cocaine in prior 6 months (n=4),current methadone (n=2) and CD4+ T-cell count (n=1).HAART, highly active
antiretroviral therapy; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; PI, protease inhibitor
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